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Dextran- Methylprednisolone Conjugates with Peptide Linkers in
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Suman Penugonda1, Hitesh K. Agarwal2, Keykavous Parang2, and Reza Mehvar1,*
1Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health
Sciences Center, Amarillo, Texas 2Department of Biomedical and Pharmaceutical Sciences,
College of Pharmacy, University of Rhode Island, Kingston, Rhode Island
Abstract
The plasma and tissue disposition of two novel dextran prodrugs of methylprednisolone (MP)
containing one (DMP-1) or five (DMP-5) amino acids as linkers were studied in rats. Single 5-mg/
kg doses (MP equivalent) of each prodrug or MP were administered intravenously, and blood and
tissue samples were collected. Prodrug and drug concentrations were quantitated using HPLC, and
non-compartmental pharmacokinetic parameters were estimated. Whereas conjugation of MP with
dextran in both prodrugs substantially decreased the clearance of the drug by ~200 fold, the
accumulations of the drug in the liver, spleen, and kidneys were significantly increased by
conjugation. However, the extent of accumulation of DMP-1 in these tissues was substantially
greater than that for DMP-5. Substantial amounts of MP were regenerated from both prodrugs in
the liver and spleen, with the rate of release from DMP-5 being twice as fast as that from DMP-1.
However, the AUCs of MP regenerated from DMP-1 in the liver and spleen were substantially
higher than those after DMP-5. In contrast, in the kidneys, the AUC of MP regenerated from
DMP-5 was higher than that after DMP-1 administration. These data suggest that DMP-1 may be
more suitable than DMP-5 for targeting immunosuppression to the liver and spleen.
Keywords
dextran prodrugs; macromolecular prodrugs; peptide linkers; methylprednisolone;
pharmacokinetics; tissue distribution; immunosuppression; liver targeting
INTRODUCTION
Intravenous mega doses (e.g., three 1-g pulses) of methylprednisolone (MP) succinate are
currently the treatment of choice, and the most widely used protocol, for the treatment of
acute cellular rejection1–4 that occurs in 60-80% of liver transplant patients.2,5 However, this
treatment has been fatal in several cases6–11 and/or associated with severe life-threatening
toxicities related to the cardiovascular system (cardiac arrest and arrhythmia),8,10–12 central
nervous system (seizure and blindness),6,13–16 severe infections (viral and bacterial),2,3,5,17
or metabolic complications (hypokalamia).18 Therefore, a targeted delivery of MP to the
liver may afford administration of smaller doses, resulting in prolonged local effects in the
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liver, without significant toxicity to other organs and sudden death observed with the current
protocols.6–11
Recently, we developed a macromolecular prodrug of MP by attaching the drug to dextran
70 kDa through a succinate linker, producing two ester bonds at both ends of the linker. The
pharmacokinetics19 and systemic20 and local21 immunosuppressive activities of the
conjugate confirmed the feasibility of the use of dextrans for delivery of MP to the liver and
spleen. These studies demonstrated that the prodrug would selectively accumulate and
gradually release MP in the liver and spleen, resulting in a more intense and sustained
immunosuppressive activity in these organs, compared to administration of an equal dose of
the parent drug. Additionally, studies in a rat transplantation model showed that this dextran
prodrug of MP is more effective than the parent drug in preventing rejection of the liver
allograft.22 However, despite very high accumulation of the prodrug in the liver and spleen,
the regeneration of MP (via enzymatic hydrolysis of the ester bonds) in these tissues was
very slow and incomplete.20,21 For example, although the concentration of the conjugate in
the spleen was still very high at 96 hr after its administration (84.2 μg/g; 50% of the peak
concentration), no free MP was detected at this time, resulting in the return of lymphocyte
proliferation activity to the baseline levels. In fact, the ratio of the regenerated MP: 70 kDa-
succinic acid-MP concentrations in the spleen progressively and rapidly declined with time
after the administration of the conjugate.20 Similarly, despite the fact that the conjugate
concentration in the liver at 72 hr after its administration was ~40% of its peak
concentration, it did not result in any MP regeneration or immunosuppressive activities in
this organ at this time point.21 This was attributed to the type of linker (succinic acid) and
steric hindrance exerted by the 70 kDa dextran.23 The slow and incomplete regeneration of
MP from the dextran 70 kDa-succinic acid-MP is undesirable because the full potentials of
the prodrug in terms of both intensity and duration of the effect are not realized. Therefore,
newer prodrugs of MP with faster and more controllable rate of release are desirable.
In an effort to improve and control the release profile of MP from its macromolecular
prodrugs, second-generation dextran-MP prodrugs were recently24 synthesized containing a
lower Mw dextran (~25 kDa) and peptide linkers of varying lengths (1–5 amino acids). In
vitro studies24 indicated that these prodrugs are subject to hydrolysis by lysosomal enzymes,
with the rate of hydrolysis being proportional to the length of the peptide linker. Therefore,
it may be possible to control the in vivo rate of release of MP from its dextran prodrugs by
using different peptide linkers. In the current study, we selected two second-generation
dextran prodrugs of MP with the shortest (one amino acid) and longest (five amino acids)
linkers for in vivo pharmacokinetic studies in rats. Single doses of dextran-MP conjugates
with one (DMP-1) or five (DMP-5) amino acid linkers (Scheme 1) or the parent drug MP
were administered to rats and their plasma pharmacokinetics and tissue disposition were
determined. Our hypothesis was that the in vivo rate of regeneration of MP from DMP-5 is
faster than that after the DMP-1 administration.
MATERIALS AND METHODS
Chemicals
Dextran with an average Mw of 23500 was obtained from Dextran Products Ltd.
(Scarborough, Ontario, Canada). The degree of polydispersity of dextran was 2.3. 6α-
Methylprednisolone (MP) was purchased from Steraloids (Newport, RI, USA). Internal
standard (triamcinolone acetonide) was purchased from Sigma (St. Louis, MO). For
chromatography, HPLC grade acetonitrile (EMD) was obtained from VWR Scientific
(Minneapolis, MN, USA). All other reagents were analytical grade and obtained through
commercial sources.
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DMP conjugates (Scheme 1) with methyl Gly (mGly) (DMP-1) or mGly-Gly-Gly-Gly-Gly
(DMP-5) were synthesized and characterized as reported by us before.24 The degrees of MP
substitution (w/w) of the conjugates were 9.4% and 6.9% for DMP-1 and DMP-5,
respectively, with purities of >90%.
Animals, Dosing, and Sampling
All procedures involving animals used in this study were consistent with the guidelines set
by the National Institute of Health (NIH Publication No. 85–23, revised 1985) and approved
by our Institutional Animal Care and Use Committee. Adult male Sprague-Dawley rats were
obtained from Charles River Lab (Wilmington, MA) and housed in a 12-h light-dark cycle
and temperature-controlled facility prior to the study. A total of 64 animals were used for
this study that consisted of 3 groups. Two groups (21 rats/group) were treated with DMP-1
or DMP-5 and the third group (18 rats) was treated with MP. The remaining four rats were
used as organ donors for blank sample preparation. The mean ± standard deviation (SD) of
the body weights of rats were 250 ± 12, 236 ± 26, and 246 ± 12 g for DMP-1, DMP-5, and
MP groups, respectively.
A single 5-mg/kg (MP equivalent) dose of either MP or dextran prodrugs of MP were
administered into the penile veins of rats under isoflurane anesthesia. The drugs were
injected as bolus doses over ~15 sec. At various times after dosing, different groups of
animals were euthanized using carbon dioxide, and blood (cardiac puncture) and tissues
were collected. The sampling times were 1 min and 0.5, 1.5, 3, 5, 12, and 24 h after DMP-1
or DMP-5 injection, and 1, 10, 20, 40, 60, and 120 min after MP injection (n = 3/time point).
Also, total urine output was collected from the 24-hr groups after the DMP-1 or DMP-5
injections. Immediately after excision, the collected tissues were rinsed in ice-cold saline
and blotted dry and kept frozen until analysis. The blood was immediately centrifuged in
heparin-coated microcentrifuge tubes to obtain plasma. One hundred microliters of plasma
sample was transferred to a silanized microcentrifuge tube for DMP analysis. For MP
analysis, 500 μL of plasma sample was transferred to a silanized microcentrifuge tube
containing 100 μL of 10% acetic acid solution to prevent DMP hydrolysis in vitro.25 All the
samples were stored at −800C until analysis.
Sample Analysis
Before analysis, tissues were homogenized with 3 volumes of 2% (v/v) acetic acid, and the
homogenate was used for the HPLC analysis of DMP and/or free MP. Previous studies have
shown that the in vitro hydrolysis of DMP conjugates with peptide linkers in the liver
homogenates containing 2% acetic acid is negligible during sample preparation.25
The concentrations of free MP in plasma and tissue homogenates were determined using a
previously reported reversed-phase HPLC method26 with a modified extraction procedure.
Briefly, to 240 μL of plasma and/or tissue homogenates were added 600 μL of cold
acetonitrile containing 5 μg/mL of triamcinolone acetonide as internal standard. After vortex
mixing and centrifugation, the supernatant was evaporated, and the analytes were first
dissolved in 120 μl of methanol, followed by the addition of 120 μL of 10 mM sodium
acetate buffer (pH 4.5). After a brief centrifugation, the resultant supernatants were injected
into the HPLC.
The concentrations of DMP in plasma were measured using a slightly modified size-
exclusion HPLC (SEC) method described before.27 To precipitate proteins, 80 μL of cold
methanol and 20 μL of 20% (v/v) perchloric acid were added to 100 μL of plasma. After a
brief vortex mixing and centrifugation, 150 μL of the supernatant was transferred to a new
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microcentrifuge tube and 175 μL of a 0.2 M phosphate buffer (pH 7.0) were added.
Subsequently, a 100-μL aliquot was subjected to the SEC method.
The concentrations of DMP in tissue homogenates were quantitated according to a
previously reported assay,19 with two minor modifications. Instead of ethanol, dextran
conjugates were precipitated with methanol, and the acetonitrile proportion in the mobile
phase was 35%, instead of 25%.
Pharmacokinetic Analysis
Non-compartmental pharmacokinetic parameters were calculated using WinNonlin 5.2.1
(Pharsight Company; Mount View, CA). The pharmacokinetic parameters obtained included
the area under the plasma concentration-time curve from time zero to the last measurable
concentration without (AUClast) and with (AUC0-∞) extrapolation to infinity, total body
clearance (CL), initial volume of distribution (V0), steady-state volume of distribution (Vss),
mean residence time (MRT), maximum observed drug concentration (Cmax), and time to
reach Cmax (Tmax). The terminal elimination rate constant (λz) was calculated from the log-
linear portion of plasma or tissue concentration-time curves. The maximum concentrations
of DMP or MP in plasma after the injection of the conjugate or parent drug (C0) were
assumed to be the same as the concentrations at the first sampling time (1 min). The
concentrations of drugs in tissues were corrected28 for the contribution from the residual
blood using the volume fraction of blood (VB) in different organs; VB values of 0.0135,
0.061, 0.0459, 0.0572, 0.175, and 0.321 were used for brain, heart, kidney, liver, lung, and
spleen, respectively.29
Statistical Analysis
Because of the destructive nature of sampling, the variance could not be estimated by
normal methods for most pharmacokinetic parameters except for Cmax, C0, V0, and the
cumulative amount excreted unchanged in urine within 24 hr ( ), which are presented as
mean ± SD. Additionally, the variance of AUClast was estimated using the Bailer method,
and the AUClast values are presented as mean ± SE.30
Statistical comparisons were conducted either between DMP-1 and DMP-5 or among parent
MP, MP regenerated from DMP-1, and MP regenerated from DMP-5. For parameters with
known variances (e.g., Cmax), statistical comparisons among three groups were tested by
one-way ANOVA, followed by Tukey’s post-hoc analysis, whereas unpaired, two-tailed t-
test was used for comparisons involving two groups (DMP-1 vs. DMP-5). The statistical
differences among different groups in their AUC values were analyzed using a two-sided Z-
test after Bonferroni adjustment for the appropriate number of comparisons, as described in
detail before.19
RESULTS
Plasma Pharmacokinetics
The plasma concentration-time courses of DMP-1, DMP-5, and MP after intravenous doses
of 5 mg/kg (MP equivalent) of the prodrugs or the parent drug are presented in Figure 1. The
plasma concentrations of MP after the administration of the parent drug were relatively low
and not detectable beyond 60 min after the drug administration. In contrast, both DMP-1 and
DMP-5 demonstrated very high concentrations, which were quantifiable for at least 5 hr.
Whereas the plasma concentrations of DMP-1 were also measurable at 12 hr in all the rats,
no detectable traces of DMP-5 were found at this time point (Fig. 1).
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After the administration of DMP-1, no regenerated MP was detectable in all the plasma
samples, except for the 1-min sample, which contained an MP concentration of 0.180 ±
0.020 μg/mL. The plasma concentrations of the regenerated MP after DMP-5 injection,
which ranged from 2.94 ± 0.83 μg/mL at 1 min to 0.239 ± 0.122 μg/mL at 3 hr (data not
shown), were higher than those after the administration of the parent drug (Fig. 1),
suggesting in vitro regeneration of MP from DMP-5 during sample collection, storage, and/
or analysis.
The pharmacokinetic parameters of MP, DMP-1, and DMP-5 are presented in Table 1.
Conjugation of MP to dextran using the mGly (DMP-1) or mGly-Gly-Gly-Gly-Gly (DMP-5)
linker resulted in a substantial (170–210 fold) reduction in the plasma clearance of the drug.
However, the CL values of the two conjugates were relatively close (Table 1). Additionally,
dextran conjugation caused substantial reductions in the overall extent of distribution of the
drug, as reflected in both V0 and VSS. However, the magnitudes of the decrease in the
volume of distribution of MP as a result of conjugation were much smaller than those
observed for the CL (Table 1). Furthermore, although the initial volumes of distribution (V0)
of the two conjugates were similar, the VSS of DMP-1 was ~4 fold larger than that for
DMP-5. The higher VSS of DMP-1 was also reflected in the longer terminal half life and
MRT for this conjugate (Table 1). Twenty four hours after the drug injection, 15.4% and
24.7% of the dose of DMP-1 and DMP-5, respectively, were recovered unchanged in the
urine (Table 1).
Tissue Disposition
The hepatic concentration-time profiles of the administered MP, DMP-1, and DMP-5 and
MP regenerated in vivo from DMP-1 and DMP-5 are presented in Figure 2. Additionally,
the respective pharmacokinetic parameters are presented in Table 2. Following the
administration of the parent drug MP to rats, the maximum liver concentrations of MP (1.14
± 0.45 μg/g) occurred within the first sample (1 min), and, thereafter, the concentrations
declined very rapidly (Fig. 2) with a terminal half life of 0.708 h (Table 2). In contrast, the
hepatic concentrations of both prodrugs DMP-1 and DMP-5, after the administration of
equivalent MP doses, were much higher than those of the parent drug and declined relatively
slowly with terminal half lives of 15.0 and 9.07 h, respectively (Fig. 2 and Table 2). Indeed,
the hepatic AUC0-∞ values of DMP-1 and DMP-5 were 760- and 220-fold, respectively,
larger than that of the parent drug (Table 2). Also, although the Cmax values of the
regenerated MP after the administration of both prodrugs were similar to that after the
administration of the parent drug (p > 0.05), they occurred at a later time, and the decline in
the hepatic concentrations of the regenerated MP after DMP-1 and DMP-5 were much more
sustained than that after the parent drug (Table 2 and Fig. 2). Therefore, the hepatic AUC0-∞
of regenerated MP after DMP-1 and DMP-5 were 14 and 10 fold, respectively, higher than
that after the administration of the parent drug (Table 2). We also estimated the liver:plasma
AUC ratios after the parent drug or prodrug administration as a measure of liver targeting.
Whereas the ratio for DMP-5 (2.98) was close to that for the parent drug (2.29), the ratio for
DMP-1 (8.40) was ~4-fold higher than that for the parent drug (Table 2).
The splenic concentration-time profiles and disposition parameters of all the administered
drugs (MP, DM-1, and DM-5) and MP regenerated from the two prodrugs are presented in
Figure 3 and Table 3, respectively. Compared with the parent drug MP, the concentrations
of the two prodrugs in the spleen were very high, with the Cmax values occurring much later.
Similar to the liver profiles (Fig. 2), DMP-1 achieved much higher concentrations in the
spleen, when compared with DMP-5 (Fig. 3). Both DMP-1 and DMP-5 released MP in the
spleen (Fig. 3). Although the Cmax values of the regenerated MP were similar after DMP-1
and DMP-5 administration, the Tmax was much longer and the AUC was substantially
higher after the DMP-1 injection (Table 3). Furthermore, the spleen: plasma AUC ratios, a
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measure of targetability to the spleen, increased from 2.90 for the parent drug to 54.8 and
10.9 for DMP-1 and DMP-5, respectively (Table 3).
In terms of tissues other than the liver and spleen, the concentrations of DMP-1 and DMP-5
in the heart and lungs were below the level of quantitation for most samples. Additionally,
no detectable peaks of DMP-1 or DMP-5 were found in any of the brain samples. However,
relatively significant concentrations of DMP-1 and DMP-5 were found in the kidneys
(Figure 4 and Table 4). Similar to the pattern in the liver and spleen, the DMP-1 AUC in the
kidney was several-fold larger than that of DMP-5. However, in contrast to the liver and
spleen, the higher and sustained concentrations of DMP-1 in the kidneys were associated
with relatively low levels of regenerated MP, which were only detectable within the first 30
min of DMP-1 injection (Figure 4).
DISCUSSION
Our recent in vitro studies24 indicated that dextran prodrugs of MP with linkers containing
1-5 (methyl) Gly residues were degraded by rat liver lysosomal fractions at a rate directly
proportional to the length of the linker. The present work was then undertaken to study the
in vivo pharmacokinetics, tissue distribution, and extent of MP regeneration of the two
prodrugs of MP with the shortest (DMP-1) and longest (DMP-5) linkers. Although both
prodrugs significantly altered the pharmacokinetics and tissue disposition of MP
qualitatively in a similar manner, substantial differences were observed between the two
prodrugs, most notably in their extent of tissue distribution and regeneration of MP (Figs. 2–
4 and Tables 2–4).
In all the studied tissues, DMP-1 achieved significantly higher concentrations (Figs. 2–4)
and AUCs (Tables 2–4), compared with those observed after DMP-5 administration,
suggesting a larger extent of distribution for this prodrug. This difference was also reflected
in a four-fold larger VSS for DMP-1, estimated from the plasma concentration data (Table
1). The significant differences between the two prodrugs in their extent of tissue distribution
suggest that the linker affects the physicochemical properties of the prodrug that are critical
in its distribution.
Alternatively, the observed differences between DMP-1 and DMP-5 in their VSS may have
been influenced by their different degrees of MP substitution (9.4% versus 6.9%,
respectively). Whereas dextrans are extremely water soluble, MP is very lipophilic.
Therefore, a 27% lower MP content of DMP-5, relative to DMP-1, may have contributed, in
part, to a lower lipophilicity of DMP-5 and a smaller VSS for this conjugate. Additionally,
because of the higher MP content, the dose of dextran backbone was 27% lower after
DMP-1 injection. However, it is unlikely that a 27% difference in the dose of the carrier
would be responsible for the 4-10 fold observed higher accumulation of DMP-1 in the
tissues (Tables 2–4).
Although less accumulated in the tissue than DMP-1, DMP-5 regenerated MP faster than did
DMP-1 in all the tissues. This is demonstrated by comparisons of the AUCs of the
regenerated MP with those of their prodrugs in each tissue. In the liver, the AUC of the
regenerated MP comprised 1.7% of the AUC of the prodrug after DMP-1 administration and
4.5% of the AUC of the prodrug after DMP-5 administration (Table 2). Similarly, in the
spleen the ratios were 1.62% and 2.94% after the DMP-1 and DMP-5 injections,
respectively (Table 3). In the kidneys, the ratio was the highest for DMP-5 (9.25%) among
all the studied tissues, whereas virtually no release of MP was observed after DMP-1
administration (Table 4). These data suggest that the in vivo release of MP from the
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prodrugs is faster for DMP-5 than DMP-1, an observation that is in complete agreement
with the in vitro release data reported by us previously.24
The faster in vivo release of MP from its dextran prodrug with the longer peptidyl linker
(DMP-5) is in agreement with the literature data on a dextran prodrug of a camptothecin
analog (T-2513), containing peptidyl linkers.31 Harada et al.31 studied the in vivo release of
T-2513 in the liver and tumor of rats bearing Walker-256 carcinomas at 6 hr after a single 1-
mg/kg dose of T-2513 conjugated to carboxymethyldextran (Mw of 130 kDa) via linkers
comprising of one to five Gly amino acids. Similar to our studies, an increase in the length
of the linker progressively increased the in vivo rate of release of T-2513. However, they did
not detect any release of T-2513 from the prodrug with Gly linker. This is in contrast to a
relatively significant release of MP from DMP-1 in the liver in our studies (Fig. 2). This
difference could be attributed to the differences in the two prodrugs in the chemistry of the
bond between the drug and the carrier and/or the much larger size of the dextran carrier used
in their study (130 kDa), compared with ours (~25 kDa).
It may be argued that the lower concentrations of DMP-5 in the tissues, compared with
DMP-1 (Figs 2-4), are due to a faster release of MP from this prodrug and not because of
differences in the tissue accumulation between the two prodrugs. Although a faster MP
release might have contributed to the lower tissue concentrations of DMP-1, in particular in
the kidneys, it cannot explain the substantial differences between the tissue AUCs of DMP-1
and DMP-5 in the liver and spleen. This is because in both the liver (Table 2) and spleen
(Table 3), the AUC of the generated MP after DMP-1 was higher than that after the
administration of DMP-5. Therefore, the differences in the tissue accumulation of the two
prodrugs, at least in the case of liver and spleen, are likely due to a selective accumulation of
DMP-1 in these tissues.
The tissue:plasma AUC ratio is a more appropriate index of tissue targeting, compared with
the absolute AUC values in the tissues. Based on these AUC ratios, both dextran prodrugs of
MP are superior to the parent drug in terms of targeting MP to the liver (Table 2), spleen
(Table 3), and kidneys (Table 4). Further, a comparison of the ratios for the two prodrugs
indicate that DMP-1 has 3, 5, and 11 fold higher selectivity for the liver, spleen, and
kidneys, respectively, compared with DMP-5. It should be noted the true index of tissue
targetability for prodrugs is the tissue:plasma AUC ratios of the regenerated drug. This
parameter was not estimated in our study because of the lack of regeneration of MP in the
plasma after DMP-1. However, it is clear that based on this parameter, the selectivity of
DMP-1 for targeting to the liver and spleen would have been even more dramatic (because
of the very low plasma concentrations of MP regenerated from DMP-1, compared with
DMP-5). However, the same may not be true for the kidneys because in this tissue, the
concentrations of MP regenerated from DMP-5 were higher than those after DMP-1 (Fig. 4).
Overall, our data indicate that although releasing MP at a slower rate, DMP-1 is superior to
DMP-5 in terms of targeting MP to the liver and spleen.
In addition to the MP prodrug developed by us, at least three other examples are available in
the literature with regard to the use of peptide linkers for the attachment of drugs to dextran
carriers.31–37 In all of these examples, carboxymethyldextran, a negatively charged
derivative of dextran, with high Mw was used as a carrier with a peptide linker with
three,31–33 four,34,35 or six36,37 amino acids to deliver anticancer drugs camptothecin
derivatives31–35 or methotrexate36,37 to the tumor. These prodrugs exhibit increased
circulation time, relative to that of the parent drug, allowing higher accumulation of the
anticancer drugs in the tumors, where they gradually release the parent drug, resulting in
higher efficacy and/or lower toxicity in animal and/or human studies. Our prodrugs intended
for the delivery of MP to the liver and spleen differ from these anticancer prodrugs mainly
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in that we used a neutral dextran, instead of the negatively charged carboxymethyldextran
used for the delivery of the anticancer drugs. This was because previous studies38 have
shown that negatively-charged dextrans have a lower accumulation in the liver, compared
with neutral dextrans. Therefore, neutral dextrans are more suitable than negatively-charged
dextrans for delivery to the liver, which is intended for our MP prodrug.
The two dextran prodrugs of MP tested in the present in vivo study (DMP-1 and DMP-5) are
part of a second-generation dextran prodrugs of MP that were recently synthesized and
characterized in vitro.24 A major difference between these prodrugs and a prodrug of MP
developed earlier (dextran 70 kDa-succinic acid-MP) is the use of amino acid/peptide linker
(instead of a succinate linker) in the new prodrugs. The peptide linkers were selected to
circumvent the inflexible and slow rate of MP regeneration observed with dextran 70 kDa-
succinic acid-MP.19,20 Indeed, whereas the ratio of the AUC of the regenerated MP over that
of the prodrug in the liver was only 0.60% for dextran 70 kDa-succinic acid-MP,19 the
corresponding ratios were 1.8% and 4.5% for DMP-1 and DMP-5, respectively (Table 2).
Similarly, the ratios for DMP-1 and DMP-5 in the spleen (1.6%, and 2.9%, respectively;
Table 3) were higher than that for dextran 70 kDa-succinic acid-MP (0.93%).19 These data
indicate that not only is the rate of MP regeneration faster with the new prodrugs, but also
can be controlled by varying the length of the linker.
The second major difference between the newly-developed prodrugs described here and
dextran 70 kDa-succinic acid-MP is the lower Mw of the new prodrugs (25 kDa instead of
70 kDa). Our previous work with dextran carriers demonstrated that high Mw dextrans (Mw
≥ 20 kDa) preferentially accumulated in the liver and spleen, whereas low Mw dextrans
(e.g., Mw of 4 kDa) were rapidly excreted into the urine without achieving significant
concentrations in the liver or spleen.28 Among dextrans with a Mw in the range of 4 kDa to
150 kDa, dextran with a Mw of 70 kDa achieved the highest accumulation in the liver.
Therefore, in our initial studies designing a prodrug of MP, we used the 70 kDa dextran as a
carrier. However, the elimination of dextran 70 kDa is strictly via non-renal pathways,28
making it susceptible to nonlinearity in its pharmacokinetics.23,39 Therefore, in designing
the newer dextran prodrugs of MP, we selected a dextran with a Mw of 25 kDa, which is
expected to be subject to some degree of linear renal excretion,39 in addition to a significant
accumulation in the liver.28 Therefore, another major difference in the pharmacokinetics of
the newer prodrugs (DMP-1 and DMP-5) and dextran 70 kDa-succinic acid-MP is that in
contrast to no renal excretion for dextran 70 kDa-succinic acid-MP, between 15% to 25% of
the administered dose of DMP-1 or DMP-5 was recovered in the 24-h urine of rats as intact
prodrug (Table 1). These data suggest that the potential for the long-term, undesired
accumulation of the carrier dextran in the tissues is less for these novel dextran prodrugs of
MP.
Our recent in vitro studies24 showed that DMP-1 and DMP-5 are degraded in the rat blood
in vitro (37°C) with half lives of 24.5 and 4.67 h, respectively. Additional studies25 also
showed that the addition of acetic acid to the plasma samples during the sample preparation
and storage prevents in vitro degradation of the prodrugs in plasma. Although blood samples
in our study were centrifuged immediately to separate plasma before the addition of acetic
acid and storage, the MP concentrations in the plasma samples of DMP-5-treated animals
were substantially higher than the corresponding concentrations after the administration of
the same dose of the parent drug (See Results). Pharmacokinetically, the AUC of a drug
after the administration of its prodrug cannot be higher than that after the administration of
the same dose of the parent drug, suggesting that despite our precautions DMP-5 was
converted to MP in the blood in vitro during centrifugation. This is a plausible explanation
because in vitro degradation of even 1-2% of the very high concentrations of the prodrug in
the plasma (Fig. 1) can easily result in the values observed after DMP-5. Consequently, we
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did not report here the plasma AUC values of MP after DMP-5 administration. This problem
did not occur with DMP-1 because of much higher stability of this prodrug, compared with
DMP-5, in blood.24 Nevertheless, our data clearly show that DMP-1 does not regenerate MP
to a significant degree in the blood (in vivo or in vitro), whereas DMP-5 is prone to the
release of MP in the blood both in vivo and in vitro.
An ideal macromolecular prodrug of a drug with its site of action in the tissue is expected to
remain intact in the circulation, enter the tissues and cells of interest, and release the drug
intracellularly. If the drug is released prematurely in the circulation, the prodrug will lose its
targeting effect, resulting in no change in drug exposure. Our tissue data for the liver (Fig. 2
and Table 2) and spleen (Fig. 3 and Table 3) for both DMP-1 and DMP-5 conjugates clearly
show that the tissue exposure to released MP was much higher, compared with the parent
drug administration. This suggests that the MP present in these tissues after the conjugate
administration is most likely regenerated from the conjugate intracellularly. This is
consistent with previous studies40,41 demonstrating that dextrans enter the cells by
endocytosis, ending up in lysosomes, which contain enzymes capable of degrading peptide
bonds such as those in DMP-1 and DMP-5.24
In conclusion, our data show that the novel dextran prodrugs of MP with amino acid/peptide
linkers are suitable for delivery of the drug to the liver and spleen for the purpose of
immunosuppression. In agreement with the reported in vitro data,24 our current in vivo study
shows that the regeneration of MP from the prodrug with the five amino acid linker
(DMP-5) is much faster than that from the prodrug with the one amino acid linker (DMP-1)
in all the tissues. However, the AUC of MP regenerated from DMP-1 is substantially higher
than that regenerated from DMP-5 in the liver and spleen. In contrast to the liver and spleen,
minimal regeneration of MP occurred in the kidneys after DMP-1 administration. Therefore,
DMP-1 may be more suitable than DMP-5 for targeting immunosuppression to the liver and
spleen. Further pharmacodynamic studies are required to determine the effects of these
prodrugs on the local immunosuppression in the liver after liver transplantation.
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Figure 1.
The plasma concentration-time courses of DMP-1, DMP-5, and MP after intravenous
administration of single 5 mg/kg (MP equivalent) doses of the prodrugs or the parent drug to
rats. The symbols and bars represent the mean and SD values, respectively (n = 3 for each
point).
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Figure 2.
The hepatic concentration-time courses of the administered DMP-1, DMP-5, and MP and
the MP regenerated from DMP-1 and DMP-5 after intravenous administration of single 5
mg/kg (MP equivalent) doses of the prodrugs or the parent drug to rats. The symbols and
bars represent the mean and SD values, respectively (n = 3 for each point).
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Figure 3.
The splenic concentration-time courses of the administered DMP-1, DMP-5, and MP and
the MP regenerated from DMP-1 and DMP-5 after intravenous administration of single 5
mg/kg (MP equivalent) doses of the prodrugs or the parent drug to rats. The symbols and
bars represent the mean and SD values, respectively (n = 3 for each point).
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Figure 4.
The kidney concentration-time courses of the administered DMP-1, DMP-5, and MP and the
MP regenerated from DMP-1 and DMP-5 after intravenous administration of single 5 mg/kg
(MP equivalent) doses of the prodrugs or the parent drug to rats. The symbols and bars
represent the mean and SD values, respectively (n = 3 for each point).
Penugonda et al. Page 15
J Pharm Sci. Author manuscript; available in PMC 2012 August 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 1.
Chemical structures of methylprednisolone (MP), MP succinate (MPS), dextran, and the two
dextran prodrugs of MP with methyl (m) Gly (DMP-1) or mGly-Gly-Gly-Gly-Gly (DMP-5)
as linkers.
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Table 1
The pharmacokinetic parameters of the parent MP, DMP-1, and DMP-5 after single 5 mg/kg (MP equivalent)
intravenous doses of the parent drug or the prodrugs
Injected Drug MP DMP-1 DMP-5
Measured Analyte MP DMP-1 DMP-5
C0 μg/mL 2.13 ± 0.27 83.4 ± 1.7 92.5 ± 8.6
V0, mL/kg 2370 ± 286 60.0 ± 1.2 54.4 ± 5.2
Vss, mL/kg 2470 365 89.5
AUClast, μg h/mL 0.468 ± 0.028 77.8 ± 4.5 74.7 ± 2.5
AUC0-∞, μg h/mL 0.480 100 80.3
CL, mL/min/kg 174 0.832 1.04
MRT, h 0.237 7.32 1.44
T1/2, h 0.183 9.02 1.57
, %Dose
-
a 15.4 ± 6.1 24.7 ± 8.5
aNot determined.
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